新闻来源:UCLA opens CAR T clinical trial targeting most common types of lymphoma and leukemia 2019年10月,加州大学洛杉矶分校琼森综合癌症中心启动了一项开创性的嵌合抗原受体(CAR)T细胞(CAR-T)免疫疗法临床试验。在这项临床试验中,CAR-T细胞将通过同时识别在B细胞淋巴瘤和白血病细胞表面上表达的两个靶标--- C...
Chen, X. et al. (2023) 'Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma.,' Journal of Clinical Oncology, 41(16_su...
T-cell lymphomaDeveloping CAR T-cells for T-lineage malignancies requires minimizing fratricide of engineered T-cells and mitigating the risk of T-cell aplasia, which may be caused by the off-tumor activity of CAR T-cells. We have developed and optimized for clinical evaluation a CAR targeting...
[1]Cwynarski K,et al.TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial[J]. Nature Medicine, 2024: 1-7.https://www.nature.com/articles/s41591-024-03326-7 [2]Derigs P,et al.Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic ...
CAR T-cell therapy is pretty new, and doctors still have a lot to learn about its long-term effects. But what they've seen so far in studies has been very promising. CAR T-cell therapy gives doctors another option for treating follicular lymphoma. It can be helpful for people whose canc...
N. Chimeric antigen receptor T-cell therapies for lymphoma. Nat. Rev. Clin. Oncol. 15, 31–46 (2018). CAS PubMed Google Scholar Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017)....
CAR-T疗法在血液肿瘤临床治疗上取得成功案例激励着学界努力摸索新的免疫细胞疗法。近几年,自然杀伤细胞(natural killer cell,NK) 成为下一个被基因工程改造的对象。NK细胞是一种天然免疫细胞,具有与T细胞完全不同的靶细胞识别方式,能泛特异性识别并杀死瘤细胞。外周血中大约90% NK细胞为 CD16+CD56dim亚群,表面表达...
高博医学（血液病）北京研究中心北京高博博仁医院潘静主任聚焦自体 CD7 CAR-T 治疗难治/复发急性T淋巴细胞白血病/淋巴瘤（r/r T-ALL/LBL），在大会发言中分享了题为“Autologous CD7 CAR T-Cell Therapy for Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma”的最新研究成果。此前，潘静主任...
16. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells [J]. Blood, 2012, 119(12): p. 2709-20. doi: 10.1182/blood-2011-10-...
knew that these patients really had very limited overall survival. What we can see in some of the long-term studies is that there are about 30% or 40% of patients who achieve durable remission after treatment with CAR T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma....